Commission Regulation (EC) No 1064/2007 of 17 September 2007 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Avilamycin (Text with EEA relevance )
Date: 2007-09-17
Institutions: European Commission
Subjects: animal product, foodstuff, material of animal origin, veterinary drug, veterinary legislation

18.9.2007

EN

Official Journal of the European Union

L 243/3

COMMISSION REGULATION (EC) No 1064/2007

of 17 September 2007

amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure
for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of
animal origin, as regards Avilamycin

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

kidney) provided that,
the substance
Avilamycin is not used in poultry species from which
eggs are produced for human consumption.

the latter,

for

Having regard to the Treaty
Community,

establishing the European

(3)

Regulation (EEC) No 2377/90 should therefore be
amended accordingly.

Having regard to Council Regulation (EEC) No 2377/90 of 26
June 1990 laying down a Community procedure for the estab-
lishment of maximum residue limits of veterinary medicinal
products in foodstuffs of animal origin (1), and in particular
Article 2 thereof,

Having regard to the opinion of
the European Medicines
Agency formulated by the Committee for Medicinal Products
for Veterinary Use,

Whereas:

(4)

(5)

An adequate period should be allowed before the applic-
ability of this Regulation in order to enable Member
States to make any adjustment which may be necessary
in the light of this Regulation to the authorisations to
place the veterinary medicinal products concerned on the
market which have been granted in accordance with
Directive 2001/82/EC of the European Parliament and
the Council of 6 November 2001 on the
of
Community
to veterinary medicinal
products (2) to take account of the provisions of this
Regulation.

relating

code

The measures provided for in this Regulation are in
accordance with
Standing
the
the
Committee on Veterinary Medicinal Products,

opinion

of

(1)

(2)

All pharmacologically active substances used in the
Community in veterinary medicinal products intended
should be evaluated in
for
accordance with Regulation (EEC) No 2377/90.

food-producing animals

HAS ADOPTED THIS REGULATION:

An application for establishing maximum residue limits
for Avilamycin, an antibiotic belonging to the group of
orthosomycins, has been submitted to the European
Medicines Agency. On the basis of the recommendation
of the Committee for Medicinal Products for Veterinary
Use, this substance should be added in Annex I to Regu-
lation (EEC) No 2377/90 for porcine species (muscle,
skin plus fat, liver and kidney), rabbit (muscle, fat, liver
and kidney) and poultry (muscle, skin plus fat, liver and

Article 1

Annex I
accordance with the Annex to this Regulation.

to Regulation (EEC) No 2377/90 is amended in

Article 2

This Regulation shall enter into force on the third day following
the European
its publication in the Official
that of
Union. It shall apply from 18 November 2007.

Journal of

(1) OJ L 224, 18.8.1990, p. 1. Regulation as

last amended by
Commission Regulation (EC) No 703/2007 (OJ L 161, 22.6.2007,
p. 28).

(2) OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive

2004/28/EC (OJ L 136, 30.4.2004, p. 58).

L 243/4

EN

Official Journal of the European Union

18.9.2007

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 17 September 2007.

For the Commission

Günter VERHEUGEN
Vice-President

18.9.2007

EN

Official Journal of the European Union

L 243/5

s
e
u
s
s
i
t

t
e
g
r
a
T

s
L
R
M

s
e
i
c
e
p
s

l
a
m
n
A

i

e
u
d
i
s
e
r

r
e
k
r
a
M

)
s
(
e
c
n
a
t
s
b
u
s

e
v
i
t
c
a

l

y
l
l
a
c
i
g
o
o
c
a
m
r
a
h
P

s
t
n
e
g
a

s
u
o
i
t
c
e
f
n
i
-
i
t
n
A

s
n
i
c
y
m
o
s
o
h
t
r

O

i

s
c
i
t
o
b
i
t
n
A

X
E
N
N
A

:
)
d
e
x
i
f

n
e
e
b

e
v
a
h

s
t
i

m

i
l

e
u
d
i
s
e
r

m
u
m
i
x
a
m

h
c
i
h
w

r
o
f

s
e
c
n
a
t
s
b
u
s

e
v
i
t
c
a

l

y
l
l
a
c
i
g
o
o
c
a
m
r
a
h
p

f
o

t
s
i
L
(

0
9
/
7
7
3
2

o
N

)

C
E
E
(

n
o
i
t
a
l
u
g
e
R

o
t

I

x
e
n
n
A

n

i

d
e
d
d
a

s
i

e
c
n
a
t
s
b
u
s

i

g
n
w
o

l
l

o
f

e
h
T

.

1

.

2
1

.

.

.

5
1
2
1

.

e
l
c
s
u
M

)
1
(

t
a
F

r
e
v
i
L

y
e
n
d
K

i

e
l
c
s
u
M

r
e
v
i
L

t
a
F

y
e
n
d
K

i

e
l
c
s
u
M

)
3
(

t
a
F

r
e
v
i
L

y
e
n
d
K

i

g
k
/
g

μ

0
5

g
k
/
g

μ

g
k
/
g

μ

g
k
/
g

μ

0
0
1

0
0
3

0
0
2

g
k
/
g

μ

0
5

g
k
/
g

μ

g
k
/
g

μ

g
k
/
g

μ

0
0
1

0
0
3

0
0
2

g
k
/
g

μ

0
5

g
k
/
g

μ

g
k
/
g

μ

g
k
/
g

μ

0
0
1

0
0
3

0
0
2

t
i
b
b
a
R

)
2
(

y
r
t
l
u
o
P

e
n
i
c
r
o
P

d
i
c
a

i

c
i
n
n
r
e
v
e
o
s
i
o
r
o
h
c
i
D

l

n
i
c
y
m
a
l
i
v
A

.
s
n
o
i
t
r
o
p
o
r
p

l
a
r
u
t
a
n

n

i

t
a
f

d
n
a

i

n
k
s

o
t

s
e
t
a
l
e
r

L
R
M

s
i
h
t

,
s
e
i
c
e
p
s

y
r
t
l
u
o
p

d
n
a

e
n
i
c
r
o
p

r
o
F

.

n
o
i
t
p
m
u
s
n
o
c

n
a
m
u
h

r
o
f

d
e
c
u
d
o
r
p

e
r
a

s
g
g
e

h
c
i
h
w

m
o
r
f

s
l
a
m
n
a

i

n

i

e
s
u

r
o
f

t
o
N

.
s
n
o
i
t
r
o
p
o
r
p

l
a
r
u
t
a
n

n

i

t
a
f

d
n
a

i

n
k
s

o
t

s
e
t
a
l
e
r

L
R
M

s
i
h
t

,
s
e
i
c
e
p
s

y
r
t
l
u
o
p

d
n
a

e
n
i
c
r
o
p

r
o
F

)
1
(

)
2
(

)
3
(